Drug Profile


Alternative Names: HMR-3647; Ketek; RU-647; RU-66647

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi; sanofi-aventis
  • Class Antibacterials; Ketolides
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Acute exacerbations of chronic bronchitis; Acute sinusitis; Community-acquired pneumonia; Gram-positive infections; Pharyngitis; Respiratory tract infections; Tonsillitis
  • Discontinued Obstetric and gynaecological infections; Pelvic inflammatory disorders; Skin and soft tissue infections; Toxoplasmosis

Most Recent Events

  • 30 Mar 2007 The EMEA has recommended restricted use of telithromycin in the treatment of bronchitis, sinusitis and tonsilitis/pharyngitis
  • 13 Feb 2007 Withdrawn for Acute exacerbations of chronic bronchitis in USA (PO)
  • 13 Feb 2007 Withdrawn for Acute sinusitis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top